Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
about
Current and emerging azole antifungal agentsThirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.Fluconazole pharmacokinetics in burn patientsGlucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid.Synthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid)Metabolism-based drug interactions involving oral azole antifungals in humans.The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review.Safety and tolerability of fluconazole in children.A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.Antifungal pharmacodynamics: review of the literature and clinical applications.Fluconazole in transplant recipients: options and limitations.Review of antifungal therapy and the severity index for assessing onychomycosis: part I.Antifungal prophylaxis during neutropenia and immunodeficiencyThe effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.Fluconazole for the treatment of candidiasis: 15 years experience.Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemiaEndogenous Candida endophthalmitis.Clinical pharmacology of antifungal agents in pediatric patients.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.A candidal oesophageal stricture responsive to fluconazole therapy.Fluconazole Pharmacokinetics in Galleria mellonella Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens.Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.Fluconazole-induced long QT syndrome via impaired human ether-a-go-go-related gene (hERG) protein trafficking in rabbits.Design, Preparation and Evaluation of HPMC-Based PAA or SA Freeze-Dried Scaffolds for Vaginal Delivery of Fluconazole.Current issues in onychomycosis.Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers.Antifungal efficacy of ten selected South African plant species against Cryptococcus neoformans.Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma.Evaluation of anti-Candida potential of geranium oil constituents against clinical isolates of Candida albicans differentially sensitive to fluconazole: inhibition of growth, dimorphism and sensitization.Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit.Pharmacokinetics and safety of Fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers.Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia.Thermoresponsive fluconazole gels for topical delivery: rheological and mechanical properties, in vitro drug release and anti-fungal efficacy.Improved efficacy of fluconazole against candidiasis using bio-based microemulsion technique
P2860
Q24550733-D3ABF4CF-D747-4C45-9C8C-F717536B5F58Q33691981-B75A6F69-7B32-4BA8-8005-E4E7779CDE10Q33692868-E14C6E17-0A40-40D6-A140-F6F5D1FCDE9AQ33693946-31F61503-FB1A-4458-BD35-52C5DF6F250FQ33719218-B12E47D5-9D79-455D-8D5E-44FE4AE82C1BQ33719828-335DAB56-E1E3-47FE-ABF2-FB188AEA1849Q33788619-5AC4BD1E-9902-4FAD-B95C-E086940AA8BAQ33977410-6EDE7E0E-6AB4-421D-8C1A-FBC817D4ADC8Q33979982-9F1C0411-5ADA-4035-9F21-A4067B304D1FQ34083129-4D70F9C7-1DFC-4A8A-B778-9E83872A6FAAQ34294909-314E3895-5B3D-4D09-B393-6351C8E2F13BQ34779001-3F186D8A-6F8C-4DDF-B3D3-01FB810444CCQ35374928-DE3E5731-211C-4CDF-A9E7-74022FA27813Q35826181-999962F7-AD31-4081-8BD5-DF9BC1A9B7F7Q35826697-51BAF3FF-F7D0-4B47-A881-133A8CC969F4Q35917407-7D6C2614-D830-4436-84EB-CD74BAF7A792Q36094974-918DB630-24C0-4FE1-8A9C-F634C21FCD56Q36607424-828C84EE-3EBB-49AD-AC59-2CD5634471D5Q36968140-92992AA7-E1C5-40A4-89F2-17F8C61A2424Q37157893-A17280EC-FE45-4477-8C12-78CA9CE55637Q38609064-83614BBF-FAD6-491A-87A3-C3009CB86F05Q38649042-87C6A271-37E7-4739-9485-F040D87A4709Q39242940-3786C228-74D6-4690-9F78-C9EF0B2E72F0Q39758352-554D1578-B803-4CA7-BFA5-97B70C09EE3DQ40135091-52506C18-B400-40F3-ADD9-582DE9643029Q41718745-468739A1-8876-4D13-9BB9-07D9F5B40BCAQ42284150-72AABE3E-EDD5-473E-A808-4A07FA73E0C7Q42964637-092D735F-7040-429A-8C1C-494D2A5A2B0CQ43015024-3CFC3424-6518-4DAA-87CE-F2DCB0AEEFE9Q43118762-8D50D38A-D373-4D4F-A32D-BD0D0CB9337DQ44437048-2E48BC9C-21BB-476A-873C-F3EC6B9A0603Q44770191-FB223468-052B-4EC7-A080-2B8DD14E8B2CQ51192914-2566FEE6-2C29-40E9-B742-D5882EB929C0Q54694844-151035A8-40C8-4B4F-BEA5-68893AA23BC2Q57173032-34462120-93B8-4585-B4D0-7B2BBFE7E7C9
P2860
Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Fluconazole. An update of its ...... in immunocompromised patients.
@en
type
label
Fluconazole. An update of its ...... in immunocompromised patients.
@en
prefLabel
Fluconazole. An update of its ...... in immunocompromised patients.
@en
P1433
P1476
Fluconazole. An update of its ...... in immunocompromised patients.
@en
P2093
L B Barradell
P304
P356
10.2165/00003495-199550040-00007
P577
1995-10-01T00:00:00Z
P6179
1004977321